Stein, S. - Search Results - UAB Digital Repository of Documents

Search collections:

Sort by:	Display results:	Output format:

Results overview: Found 4 records in 0.02 seconds.
Articles, 4 records found

Articles	4 records found

11 p, 588.4 KB

Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma : results from the randomised phase III KEYNOTE-062 study / Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Valderrama, A. (Center for Observational and Real-World Evidence, Merck) ; Bang, Yung-Jue (Seoul National University College of Medicine) ; Fuchs, C. S. (Yale University Cancer Center) ; Shitara, Kohei (National Cancer Center Hospital East, Kashiwa, Japan) ; Janjigian, Y. Y. (Memorial Sloan Kettering Cancer Center) ; Qin, S. (PLA Cancer Centre of Nanjing Bayi Hospital) ; Larson, T. G. (Minnesota Oncology Hematology) ; Shankaran, V. (Seattle Cancer Care Alliance) ; Stein, S. (Yale University Cancer Center) ; Norquist, J. M. (Center for Observational and Real-World Evidence, Merck) ; Kher, U. (Department of Medical Oncology, Merck) ; Shah, S. (Department of Medical Oncology, Merck) ; Alsina, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (GEJ) cancer. [...]
2021 - DOI (Digital Object Identifier)

10.1016/j.esmoop.2021.100189
ESMO open, Vol. 6 (august 2021)

Detailed record -

7 p, 820.3 KB

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation / Stein, A. S. (Gehr Family Center for Leukemia Research. City of Hope) ; Kantarjian, H. (The University of Texas M.D. Anderson Cancer Center) ; Gökbuget, N. (Department of Medicine II. Goethe University) ; Bargou, R. C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg) ; Litzow, Mark R (Mayo Clinic) ; Rambaldi, Alessandro (Department of Oncology and Hemato-Oncology. University of Milan and Azienda Pope John XXIII Hospital) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zhang, A. (Amgen Inc.) ; Zimmerman, Z. (Amgen Inc.) ; Zugmaier, Gerhard (Amgen Research Munich) ; Topp, M. S. (Medical Clinic and Polyclinic II. University Hospital Würzburg) ; Universitat Autònoma de Barcelona
Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation (alloHSCT) have a poor prognosis, and alternative therapies are needed for this patient population. [...]
2019 - DOI (Digital Object Identifier)

10.1016/j.bbmt.2019.04.010
Biology of blood and marrow transplantation, Vol. 25 Núm. 8 (august 2019) , p. 1498-1504

Detailed record -

$Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab$

6 p, 186.9 KB

Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab / Topp, Max S. (Universitätsklinikum Würzburg) ; Gökbuget, Nicola (Goethe University) ; Zugmaier, Gerhard (Amgen GmbH) ; Stein, Anthony S. (Gehr Family Center for Leukemia Research. City of Hope) ; Dombret, Hervé (Saint Louis Hospital. University of Paris) ; Chen, Yuqi (Amgen. Inc) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bargou, Ralf C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg) ; Horst, Heinz-August (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Kantarjian, H. M. (The University of Texas MD Anderson Cancer Center) ; Universitat Autònoma de Barcelona
Background: Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that mediates the lysis of cells expressing CD19. Methods: A pooled analysis of long-term follow-up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chromosome-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia was conducted. [...]
2021 - DOI (Digital Object Identifier)

10.1002/cncr.33298
Cancer, Vol. 127 Núm. 4 (15 2021) , p. 554-559

Detailed record -

$Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia$

7 p, 171.0 KB

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia / Rambaldi, Alessandro (Department of Oncology and Hematology. University of Milan) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Kantarjian, H. M. (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Dombret, Hervé (Department of Hematology. Hopital Saint-Louis. Paris Diderot University) ; Ottmann, O. G. (Division of Cancer and Genetics. School of Medicine. Cardiff University) ; Stein, A. S. (Gehr Family Center for Leukemia Research. City of Hope) ; Tuglus, C. A. (Amgen. Inc) ; Zhao, X. (Amgen. Inc) ; Kim, C. (Amgen. Inc) ; Martinelli, Giovanni (Scientific Institute of Romagna for the Study and Treatment of Cancer) ; Universitat Autònoma de Barcelona
Background: A single-arm, phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bispecific T-cell-engaging antibody construct, in patients with relapsed/refractory (r/r) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), a rare hematologic malignancy with limited treatment options. [...]
2020 - DOI (Digital Object Identifier)

10.1002/cncr.32558
Cancer, Vol. 126 Núm. 2 (15 2020) , p. 304-310

Detailed record -

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.